Lisata unit Marea to present Phase 2b TYDAL data on MAR001 at AHA Scientific Sessions 2026

By Public Technologies
  • Lisata announced a late-breaking presentation of Phase 2b TYDAL trial data for MAR001 at AHA Scientific Sessions 2026.
  • Results have not yet been presented; the session is scheduled for Nov. 9, 2026, in Chicago.
  • MAR001 targets ANGPTL4, aiming to lower triglycerides and improve metabolic health in adults with elevated triglycerides and remnant cholesterol.
  • MAR005, a longer-acting version, is positioned as the planned Phase 3 candidate for severe hypertriglyceridemia.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lisata Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609240800PRIMZONEFULLFEED9833009) on September 24, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk